Generali has expanded its footprint in Bulgaria by acquiring one of the top health insurers on the market
Doverie United Holding has successfully completed the sale of United Health Insurance Fund Doverie (Doverie) to Generali CEE Holding.
Doverie is one of the largest private health insurance companies in Bulgaria. As one of the first health insurance funds in the country, it ranked among the top three in 2024 by premium revenue.
Generali, the Italian insurance company and one of the world’s leading insurance providers, has acquired Doverie as part of its growth strategy in the Central and Eastern Europe (CEE) region. With this acquisition, Generali will become the second-largest player in Bulgaria’s health insurance market.
Doverie United Holding is a renowned publicly listed equity fund in Bulgaria, with a diverse portfolio that includes 18 companies across eight economic sectors.
Oaklins’ team in Bulgaria acted as the exclusive sell-side M&A adviser to Doverie United Holding, assisting the client throughout the entire divestment process.
We are now delighted that, with this transaction, Doverie has found in Generali the strategic partner that can continue the development trajectory of the business and bring it to the next level of growth. We are also thankful to Oaklins’ Bulgarian team for its professionalism and dedication throughout the deal. They were instrumental in managing the relationship between all the stakeholders, the negotiation process and the execution of the transaction.”
Alexander Hristov
CEO, Doverie United Holding
Prata med transaktionsteamet
Relaterade affärer
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer